Maintenance of remission among patients with inflammatory bowel disease after vedolizumab is stopped: a multicenter cohort study from the GETAID

(1) Henri Mondor Hospital, APHP Dept. of Gastroenterology,Creteil,France

(2) Lille University Hospital,Lille,France

(3) Nancy University Hospital Inserm U 954,Vandoeuvre les Nancy,France

(4) CHU Beaujon Dept. of IBD and Nutrition,Clichy,France

(5) Hospices Civils de Lyon,Lyon,France

(6) Gastroenterology & Nutrition Dept.,Paris,France

(7) Hopital Nord,Marseille,France

(8) Amiens University Hospital,Amiens,France

(9) CHU Estaing Clermont-Ferrand,Clermont-Ferrand,France

(10) CHU de Bordeaux Hopital Haut-Leveque,Pessac Cedex,France

(11) Hopital Rangueil,Toulouse,France

(12) Hopital de l'Achet,Nice Cedex 3,France

(13) Hopital Saint-Louis APHP, Université Denis Diderot Paris 7,Paris,France

(14) CHU Pontchaillou,Rennes,France

(15) University of St. Etienne Dept. de Gastroenterologie,Saint Etienne,France

(16) Hopital Saint Eloi,Montpellier Cedex,France

(17) Chu Angers - Hotel Dieu,Angers,France

(18) Hopital Saint Eloi Hepatologie Gastroenterologie,Montpellier cedex 5,France

(19) Hopiaux de Rouen,Rouen,France

(20) CHU Bicetre,Le Kremlin Bicetre,France

(21) CHRU de Caen HGE,Caen Cedex,France

(22) Henri Mondor Hospital, APHP,Creteil,France



This item was part of the Paradigm shifts in IBD treatment session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019